» Articles » PMID: 10398427

CDKN2A (P16(INK4a)) and CDK4 Mutation Analysis in 131 Australian Melanoma Probands: Effect of Family History and Multiple Primary Melanomas

Overview
Date 1999 Jul 9
PMID 10398427
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Mutation analysis of two genes involved in melanoma susceptibility (CDKN2A/p16(INK4a) and CDK4) was undertaken in 131 probands with a family history of melanoma. Screening of all three exons of CDKN2A and exon 2 of CDK4 by single-strand conformation polymorphism (SSCP) analysis and/or direct sequencing identified a total of 10 different CDKN2A germline mutations, including 6 not previously described in the germline. All but one has been previously proven to, or is likely to, affect the structure and function of p16(INK4a). The incidence of CDKN2A mutation was 8.4% (11/131), but was significantly higher in families with three or more cases of melanoma (10/66, 15.1%) than in those in which only two relatives were affected (1/65, 1.5%). The incidence of CDKN2A mutation was also higher in families with three or more cases of melanoma and at least one member with multiple primary melanomas (6/19, 31.6%) than in similar families without multiple primary melanomas (4/47, 8.5%). One novel CDK4 variant of uncertain significance was found in a kindred that also carries a CDKN2A mutation. Genes Chromosomes Cancer 25:339-348, 1999.

Citing Articles

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.

Mirabello L, Koster R, Karlins E, Dean M, Yeager M, Gianferante M JAMA Oncol. 2020; 6(5):724-734.

PMID: 32191290 PMC: 7082769. DOI: 10.1001/jamaoncol.2020.0197.


The digital age of melanoma management: detection and diagnostics.

Fogel A, Sarin K Melanoma Manag. 2018; 2(4):383-391.

PMID: 30190865 PMC: 6094706. DOI: 10.2217/mmt.15.31.


Outcomes and Risk Factors in Patients with Multiple Primary Melanomas.

Nosrati A, Yu W, McGuire J, Griffin A, de Souza J, Singh R J Invest Dermatol. 2018; 139(1):195-201.

PMID: 30031745 PMC: 9191767. DOI: 10.1016/j.jid.2018.07.009.


Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility.

Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti R, Limonta P Front Endocrinol (Lausanne). 2016; 7:140.

PMID: 27833586 PMC: 5080294. DOI: 10.3389/fendo.2016.00140.


State of melanoma: an historic overview of a field in transition.

Gorantla V, Kirkwood J Hematol Oncol Clin North Am. 2014; 28(3):415-35.

PMID: 24880939 PMC: 4040458. DOI: 10.1016/j.hoc.2014.02.010.